We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Incyte (INCY)
INCY 85.70-0.4%Jan 27 4:00 PM EST

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: scaram(o)uche8/29/2013 5:15:57 PM
1 Recommendation

Recommended By

  Read Replies (3) of 3202
c-MET inhibitor (INC280, entered phase II for hepatocellular carcinoma in April) is entering at least two new Novartis trials, including recurrent glioblastoma with a pan-pi3k inhibitor.......

and in combo with a b-raf inhibitor, melanoma.....

There's also a new U.C. Davis/NCI study, with tarceva in nsclc. A list of all trials at listed under "INC280"....
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext